Volume 138, Issue 4, Pages 1365-1373.e2 (April 2010) Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection  John McHutchison, Zachary Goodman, Keyur Patel, Hala Makhlouf, Maribel Rodriguez–Torres, Mitchell Shiffman, Don Rockey, Petr Husa, Wan–Long Chuang, Robert Levine, Mark Jonas, Dickens Theodore, Richard Brigandi, Alison Webster, Margaret Schultz, Helen Watson, Britt Stancil, Stephen Gardner  Gastroenterology  Volume 138, Issue 4, Pages 1365-1373.e2 (April 2010) DOI: 10.1053/j.gastro.2009.12.003 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 Paired liver biopsy specimens from a single patient stained with picrosirius red for collagen. Baseline biopsy specimen (left) has fraction of pixels positive for collagen of 0.095. Week 52 biopsy specimen (right) clearly has more red staining and by morphometry has 0.204 of the total pixels positive for collagen. Gastroenterology 2010 138, 1365-1373.e2DOI: (10.1053/j.gastro.2009.12.003) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 High magnification of liver biopsy specimens from same patient in Figure 1, stained for SMA to demonstrate activated stellate cells. In baseline biopsy specimen (left), the fraction of darkly stained pixels is 0.050 of total pixels. In the week 52 biopsy specimen (right), 0.102 of the total pixels are positive for SMA. Gastroenterology 2010 138, 1365-1373.e2DOI: (10.1053/j.gastro.2009.12.003) Copyright © 2010 AGA Institute Terms and Conditions

Figure 3 Change from baseline in steatosis grade at week 52. There was no significant change at week 52 in overall steatosis grades between the groups, although there is a trend towards improvement in the proportion of patients with grade 2 (6%–33%) or 3 (34%–66%) steatosis in the farglitizar 1-mg cohort. Gastroenterology 2010 138, 1365-1373.e2DOI: (10.1053/j.gastro.2009.12.003) Copyright © 2010 AGA Institute Terms and Conditions

Supplementary Figure 1 Of 585 CHC patients with screening biopsy, 265 were randomized to receive placebo (n = 88), Farglitizar 0.5 mg (n = 89) or 1.0 mg (n = 88). Most patients were able to complete study assessments, with reasons for discontinuation as shown. Gastroenterology 2010 138, 1365-1373.e2DOI: (10.1053/j.gastro.2009.12.003) Copyright © 2010 AGA Institute Terms and Conditions